Valuation: HOOA PHARPAR

Market Cap 11.44M 10M 9.23M 8.51M 16.03M 1.1B 16.39M 110M 43.38M 540M 42.98M 42.03M 1.86B P/E 2023
-0.94x
P/E 2024 -0.58x
Enterprise Value -27.37M -23.91M -22.07M -20.34M -38.34M -2.64B -39.19M -264M -104M -1.29B -103M -101M -4.44B EV / Sales 2023
-0.45x
EV / Sales 2024 -0.31x
Free-Float
65.98%
Yield 2023 *
-
Yield 2024 -
1 day+0.88%
6 months+22.99%
Current year+28.78%
Current year 0.88
Extreme 0.884
1.2
1 year 0.81
Extreme 0.811
1.2
3 years 0.72
Extreme 0.721
11.3
5 years 0.72
Extreme 0.721
83.9
10 years 0.72
Extreme 0.721
200
Manager TitleAgeSince
Chief Executive Officer 63 2024-07-21
Director of Finance/CFO 64 2024-07-21
Chief Tech/Sci/R&D Officer 48 2018-12-31
Director TitleAgeSince
Chairman 60 2024-08-29
Director/Board Member 53 2019-04-24
Director/Board Member 63 2022-12-31
Date Insider Type Main position Quantity % Market Cap.
8/19/25 Sell

Chief Executive Officer

25,172 0.2607%
7/22/25 Sell

Chief Financial Officer

13,609 0.1410%
7/22/25 Sell

Chief Executive Officer

29,176 0.3022%
Change 5-day change 1-year change 3-year change Capi.($)
+0.88%-.--%+0.88%-86.96% 14.79M
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+0.71%-6.01%+4.32%+424.95% 23.29B
-0.05%+0.27%-17.38%-14.43% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.01%-1.19%+24.43%+190.93% 14B
Average -2.43%-1.38%+39.70%+158.39% 24.05B
Weighted average by Cap. -2.93%-2.20%+43.32%+145.16%

Financials

2023 2024
Net sales 20.13M 17.59M 16.23M 14.96M 28.2M 1.94B 28.83M 194M 76.31M 949M 75.59M 73.94M 3.27B 43.95M 38.4M 35.44M 32.67M 61.57M 4.23B 62.94M 424M 167M 2.07B 165M 161M 7.14B
Net income -81.58M -71.29M -65.79M -60.64M -114M -7.86B -117M -786M -309M -3.85B -306M -300M -13.25B -43.5M -38.02M -35.08M -32.34M -60.95M -4.19B -62.3M -419M -165M -2.05B -163M -160M -7.06B
Net Debt -111M -96.6M -89.14M -82.16M -155M -10.64B -158M -1.07B -419M -5.21B -415M -406M -17.95B -38.81M -33.92M -31.3M -28.85M -54.37M -3.74B -55.58M -374M -147M -1.83B -146M -143M -6.3B
Logo HOOA PHARPAR
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that is designed to target and amplify T cell and immune responses to fight diseases. The Company's replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. The Company is also engaged in the assessment of strategic alternatives and the development of infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are developed in a partnership with Gilead Sciences Inc.
Employees
85
  1. Stock Market
  2. Stocks
  3. HOOK Stock